{"commentary":{"count":4,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":3,"youtube":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NERO","nct_id":"NCT05455424","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nero-nct05455424. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"NERO","arms":[{"description":"Patients will receive 200/300 mg of niraparib daily for study period of up to 24 weeks. Patients will be treated until disease progression, withdrawal, death or development of significant treatment limiting toxicity. Niraparib will be supplied in oral formulation as 100 mg capsules. The starting dose of Niraparib will be based upon the patient's baseline body weight and/or platelet count:\n\nParticipants with a baseline body weight ≥77 kg and baseline platelet count ≥150 x 109/L will be administered niraparib 300 mg daily.\n\nParticipants with a baseline body weight \\<77 kg or baseline platelet count \\<150 x 109/L will be administered niraparib 200 mg daily.\n\nThe dose of Niraparib can be reduced in 100 mg increments, to a minimum of 100 mg, per protocol. Dose escalations are not permitted.","label":"Niraparib + ASC","type":"EXPERIMENTAL"},{"description":"Patients in this arm will be managed symptomatically and will be treated as per the standard of care at each participating site. ASC could involve regular specialist follow up; structured assessment of physical, psychological, and social problems; and appropriate treatment, including palliative radiotherapy and steroids.","label":"Active Symptom Control","type":"ACTIVE_COMPARATOR"}],"collaborators":["University of Southampton","British Lung Foundation"],"completion_date":{"date":"2025-01-31","type":"ACTUAL"},"conditions":["Mesothelioma, Malignant"],"enrollment":{"count":88,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Niraparib Oral Product","type":"DRUG"},{"name":"Active Symptom Control","type":"OTHER"}],"last_update":"2025-05-15","lead_sponsor":"University Hospital Southampton NHS Foundation Trust","official_title":"Niraparib Efficacy in Patient With Unresectable Mesothelioma: A Randomised Phase II Trial of Niraparib Versus Active Symptom Control in Patients With Previously Treated Mesothelioma","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-01-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free survival","timeFrame":"From date of randomisation until the date of the first documented progression or date of death from any cause, whichever came first, assessed up to 18 months"}],"references":[{"citation":"Fennell D, Griffiths D, Eminton Z, Morgan-Fox A, Hill K, Ewings S, Stuart C, Johnson L, Mallard K, Nye M, Darlison L, Dulloo S, Cave J, Luo JL, Taylor P, Spicer J, Poile C, Bzura A, Griffiths G. Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres. BMJ Open. 2023 Nov 22;13(11):e073120. doi: 10.1136/bmjopen-2023-073120.","pmid":"37993149","type":"DERIVED"}],"start_date":{"date":"2022-07-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Niraparib Efficacy in Patient With Unresectable Mesothelioma","url":"https://clinicaltrials.gov/study/NCT05455424"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nero-nct05455424"}